Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.

Molecular cancer - 25 Jan 2017

Parasramka Mansi, Yan Irene K, Wang Xue, Nguyen Phuong, Matsuda Akiko, Maji Sayantan, Foye Catherine, Asmann Yan, Patel Tushar

Abstract excerpt

BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. METHODS: The impact of BAP1 expression on sensitivity to therapeutic agents was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Deoxycytidine

Share to Drug Synergism

Share to Gemcitabine

Share to RNA, Long Noncoding

Share to Ubiquitin Thiolesterase

Source

Open in PubMed Open full text

Identifiers

PMID: 28122578
DOI: 10.1186/s12943-017-0587-x
PMCID: PMC5264287

Genes

BAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.PMID 28122578Read ↗

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity Read ↗

Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.Semantic proximity Read ↗

Long Noncoding RNA NEAT1 Promotes Growth and Metastasis of Cholangiocarcinoma CellsSemantic proximity Read ↗

PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Semantic proximity Read ↗

The role of lncRNA NEAT1 in human cancer chemoresistanceSemantic proximity Read ↗

HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in CholangiocarcinomaSemantic proximity Read ↗

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database AnalysisSemantic proximity Read ↗

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.